COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Aleksandra Majchrzak-CelińskaJulia O MisiorekNastassia KruhleniaLukasz PrzybylRobert KleszczKatarzyna RolleVioletta Krajka-KuzniakPublished in: BMC cancer (2021)
Not only celecoxib, but also 2,5-DMC, etori-, rofe- and valdecoxib should be further investigated as potential good anti-GBM therapeutics.